Results 221 to 230 of about 116,720 (351)

Dualistic Roles of High Mobility Group Box 1 in Cancer and Inflammation

open access: yesCancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background The High Mobility Group Box 1 (HMGB1) protein, a member of the HMG family, plays a crucial role in both cancer progression and inflammatory responses. HMGB1 can act as a damage‐associated molecular pattern (DAMP) to activate immune responses and modulate inflammation.
Wen Zeng   +6 more
wiley   +1 more source

Nasal cavity and sinuses in equines [PDF]

open access: yes, 2013
Crijns, Casper   +2 more
core   +1 more source

A Multicenter, Randomized, Controlled Clinical Trial on the Efficacy and Safety of Eucalyptol, Limonene, and Pinene Enteric Capsules in the Treatment of Chronic Rhinosinusitis With Nasal Polyps Postoperatively

open access: yesClinical and Translational Allergy, Volume 15, Issue 12, December 2025.
ABSTRACT Background Eucalyptol, limonene, and pinene enteric capsules (ELP) are typical mucoactive drugs used in chronic rhinosinusitis with nasal polyps (CRSwNP). However, reliable evidence regarding its efficacy in this population remains limited.
Yutong Sima   +21 more
wiley   +1 more source

Efficacy of Dupilumab in a Woman With Severe Asthma Complicated by Eosinophilic Sinusitis and a Desire to Have a Baby: A Case Report. [PDF]

open access: yesClin Case Rep
Neoi A   +17 more
europepmc   +1 more source

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, Volume 14, Issue 12, Page 934-950, December 2025.
Abstract This 2‐part, randomized, placebo‐controlled, double‐blind, Phase 1 study analyzed the pharmacokinetics, safety, and biomarker profile of fezolinetant in healthy Japanese individuals. Part 1: male participants received single doses of placebo or fezolinetant 15 or 60 mg.
Akira Koibuchi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy